diabetes Flashcards
Dx of prediabetes
- A1c: 5.7-6.4%
- FPG:100-125
- OGTT: 140-199
Dx of DM
- A1c >6.5
- FPG: >126
- OGTT: > 200
glycemic target in DM: not pregnant
A1c: <7
pre-prandial: 80-130
2-hr PPG: <180
glycemic target in DM: pregnant
pre-prandial: < 95
1-hr PPG: < 140
2-hr PPG: < 120
microvascular disease
retinopathy, DKD, peripheral neuropathy, autonomic neuropathy (gastroparesis, loss of bladder control, ED)
macrovascular disease
CAD, CVA, PAD`
ASA for ppx in DM
recommended for secondary prevention or in pregnancy to prevent preclampsia
Cholesterol control in DM
-high intensity statin: for those with DM + ASCVD or those 50-75 w/ multiple ASCVD risk factors
-moderate intensity statin: DM + 40-75 years (no ASCVD) and DM + <40 + ASCVD risk factors
-if on maximally tolerated statin and still not at goal can add ezetimibe
diabetic retinopathy
eye exam
vaccinations for patients with diabetes
HBV, influenza, pneumococcal
DKD
-monitor urine albumin and eGFR annually
-treat albuminuria with ACEi or ARB
-if eGFR > 25 mL/min and urine albumin > 300: SGLT2
neuropathy
-foot exams
-pregabalin, duloxetine, or gabapentin
blood pressure
- <130/80 mmHg (if ASCVD > 15%)
- <140/80 mmHg (if ASCVD < 15%)
-no albuminuria: thiazide, DHP CCB, ACEi, or ARB
-albuminuria: ACEi or ARB
-CAD: ACEi or ARB
natural products
cinnamon, alpha lipoic acid, chromium
first-line treatment for T2DM
metformin + life style changes
second drug regardless to A1c
-ASCVD or high risk: GLP-1a or SGLT2
-HF: SGLT2
-CKD: SGLT2 or GLP-1a
-if ASCVD or high risk and still above goal: add GLP-1 or SGLT2 (if not added), TZD, basal insulin, SU, DPP-4i
DO NOT COMBINE
DPP-4i + GLP-1a
SU + Insulin
second drug if A1c is above goal & no ASCVD, HF, or CKD
-any class
-consider hypoglycemic risk, weight loss/gain potential, cost
-best for hypoglycemic risk: DPP-4i, GLP-1a, SGLT2, TZD
-best for weight loss: GLP-1a or SGLT2
-best for cost: SU or TZD
Biguanide
-decreasing hepatic glucose production, increasing insulin sensitivity, and decreasing intestinal absorption of glucose
-Metformin (Glucophage, Glucophage XR, Fortamet, Glumetza)
-lactic acidosis (risk increases with renal dysfunction)
-contraindicated in eGFR < 30 and do not start if eGFR 30-45
-diarrhea and nausea
-decrease A1c 1-2%, weight neutral, no hypoglycemia
SGLT2
-Canagliflozin (Invokana); Dapagliflozin (Farxiga); Empagloflozin (Jardiance)
-ketoacidosis
-genital mycotic infections, urosepsis, pyelonephritis, nec fasc (perineum)
-hypotension and AKI
-invokana: incr risk of leg and foot amputations - do not use in eGFR <30 unless albuminuria > 300
-farxiga: do not start in eGFR < 25
-Jardiance: do not use for glycemic control in eGFR < 30
-weight loss, incr urination, incr thirst
Glucagon-like peptide 1 agonists (GLP-1a)
-incr glucose-dependent insulin secretion, decrease glucagon secretion, slow gastric emptying, improves satiety
-liraglutide (victoza); Dulaglutide (Trulicity)
-increased risk of thyroid C cell carcinoma
-Warnings: pancreatitis, is not recommended in patients with severe GI disease
-Side effects: weight loss, nausea
-do not use with DPP4-i
Insulin secretagogues: SU
-Glipizide (Glucotrol, Glucotrol XL); Glimepiride (Amaryl); Glyburide
-do not use in those with sulfa allergy
-highest risk of hypoglycemia
-decreases A1c by 1-2%
-Glucotrol XL produces a ghost tablet
Insulin secretagogues: meglitinides
-repaglinide and nateglinide
-hypoglycemia
-weight gain
Dipeptidyl Peptidase 4 inhibitors (DPP4-i)
-prevent DPP4 from breaking down incretin hormones
-sitagliptin (Januvia); Linagliptin (Tradjenta)
-sitagliptin requires renal adjustment for eGR 30 and less
-warnings: pancreatitis, arthralgias, renal failure
-DO NOT USE WITH GLP1-a
TZDs
-PPARy agonists that increase peripheral insulin sensitivity
-pioglitazone (Actos); Rosiglitazone (Avandia)
-exacerbate HF (DO NOT USE WITH NYHA III/IV), edema, risk of fractures
Alpha-Glucosidase inhibitors
-Acarbose (Precose)
-inhibit metabolism of intestinal sucrose
-each dose should be taken with first bite of each meal
Metformin/pioglitazone (Actoplus)
metformin + TZD
Metformin/sitagliptin (Janumet)
metformin + DPP-4 inhibitor
Metformin/Canagliflozin (Invokamet)
metformin + SGLT2
Basal insulin
glargine (Lantus, Toujeo), detemir (levemir), degludec (Tresiba - extra long acting)
-peakless
-onset of 3-4 hrs and duration > 24 hrs
-impact fasting glucose
-Lantus is 100 IU, toujeo is concentrated at 300 IU/mL
intermediate-acting insulin
-insulin NPH
-can be used as basal insulin
-onset of 1-2 hrs and peaks at 4-12 hrs
-dosed BID